- Glaxo Wellcome's appeal to get a UK High Court ruling in favor of the Inland Revenue with respect to collecting back taxes reversed, has failed (Marketletter November 20). But GW stresses that this does not in itself indicate any tax liabilities on its part, and annual accounts have consistently stated that adequate tax liability provisions have been made.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze